ГоловнаArchive of numbers2022Volume 30, issue 2(111)The place of gabapentinoids in providing specialized care to patients with mental and behavioral disorders according to the principles of evidence-based medicine (literature review)
Title of the article The place of gabapentinoids in providing specialized care to patients with mental and behavioral disorders according to the principles of evidence-based medicine (literature review)
Authors Markozova Lubov
In the section LITERATURE REVIEW
Year 2022 Issue Volume 30, issue 2(111) Pages 74-80
Type of article Scientific article Index UDK 616.89-008.447:615.213 Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V30-is2-2022-12

 The article considers the problem of the use of gabapentinoids at the present stage to persons with men- tal and behavioral disorders according to the principles of evidence-based medicine based on the literature and the author’s own experience; the ab- sence of a common opinion among the authors is determined; conclusions are drawn that the use of gabapentinoids to persons with mental and behavioral disorders are not for their intended purpose; the necessity of maintaining a balance between the potential ben- efits and the risk of harm and taking into account the high potential for the deve- lopment of dependence on gabapenti- noids in patients with different nosolo- gies is emphasized, and therefore the appointment of gabapentinoids is not recommended for providing specialized care to patients as monotherapy, the question of the effectiveness of combi- nation therapy remains open. The use of gabapentinoids is not recommended for providing specialized care for people with dependence on alcohol and other psychoactive substances, or with any other type of dependence. The features of the use of gabapentinoids in elderly patients and people with opioid depen- dence are determined.
Key words mental and behavioral disorders, alcohol dependence, medical care, gabapentinoids
Access to full text version of the article pdf download
Bibliography 1. Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcoholuse disorder. Expert Opin Investig Drugs. 2018. Jan. 27(1). 113–124. https://doi.10.1080/13543784.2018.1417383.
2. Ahmed S, Stanciu CN, Kotapati PV, et al. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. Prim Care Companion CNS Disord. 2019; 21(4): 19r02465. https://doi.10.4088/PCC.19r02465.
 3. Jonathan G Leung, Daniel Hall–Flavin, Sarah Nelson et al. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015. 49(8). 897–906. https://doi.10.1177/1060028015585849.
4. Markozova L. M. Problema zastosuvannia haba penty- noidiv v medychnii praktytsi. Materialy naukovo-praktychnoi konf. "Shchorichni terapevtychni chytannia. Neinfektsiini zakh- voriuvannia: profilaktyka ta zmitsnennia zdorov’ia v Ukraini", 22—23 kvitnia 2021 r., m. Kharkiv. S. 84.
5. Antiufieiev O. V. Zalezhnist vid prehabalinu — lirika, linbah, neohabin i habany. https://renessans-center.com/uk/likuvannya- -narkomaniji/zalezhnist-vid-pregabalinu-neogabin-lirika-alge- rika-ta-gabana.
6. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, de- pendence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 2019 Aug. Vol. 15(8). P. 953-958. https:// doi.org/10.1016/j.sapharm.2018.06.018.
7. Mersfelder TL, Nichols WH. Gabapentin: Abuse, Depen- dence, and Withdrawal. Ann Pharmacother. 2016. 50(3). 229–233. https://doi.10.1177/1060028015620800.
8. Huiqiong Deng, Ori–Michael Benhamou, Anna Lembke. Gabapentin dependence and withdrawal requiring an 18–month taper in a patient with alcohol use disorder: a case report. J Addict Dis. Oct–Dec 2021. 39(4). 575–578. https://doi.10.108 0/10550887.2021.1907502.
9. Latest advice for medicines users. Drug Safety Update. MHRA: The monthly newsletter. Vol. 12, issue 9: April 2019: P. 9-10. URI: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/795950/April- 2019-PDF-final.pdf.
10. Charles V. Preuss, Arun Kalava, Kevin C. King. Prescription of Controlled Substances: Benefits and Risks. In: StatPearls [In- ternet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 30726003.
11. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. British Journal of Pain. 2020.May,14(2). 104–114. https:// doi.10.1177/2049463720912496
12. Houghton KT, Forrest A, Awad A, et al. Biological ratio- nale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a sys- tematic review and meta-analysis. BMJ Open. 2017. Mar 27; 7(3). e013433. https://doi.10.1136/bmjopen–2016–013433.

13. Ng QX, Han MX, Teoh SE, et al. A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder. Pharmaceuticals (Basel, Switzerland). 2021 Aug; 14(9): 834. DOI: 10.3390/ph14090834.
14. Lo YC, Liao KK, Lee YC, Soong BW. Gabapentin for comp- lex regional pain syndrome in Machado-Joseph disease: a case report. J Med Case Rep. 2011 Jul 1; 5: 268. doi: 10.1186/1752- 1947-5-268.
15. Taylor, SS., Noor, N., Urits, I. et al. Complex Regional Pain Syndrome: A Comprehensive Review. Pain Ther. 10, 875–892 (2021). https://doi.org/10.1007/s40122-021-00279-4.
16. Frenette E. Restless legs syndrome in children: a review and update on pharmacological options. Current Pharmaceutical Design. 2011. 17(15). 1436–42. https://doi.10.2174/138161211796197142.
17. Bruni O, Angriman M, Melegari MG, Ferri R. Pharmacothera- peutic management of sleep disorders in children with neurode- velopmental disorders. Expert Opin Pharmacother. 2019. 22 Oct. 20(18). 2257–2271. https://doi.10.1080/14656566.2019.1674283.
18. Biyik Z, Solak Y, Atalay H. et al. Gabapentin versus pre- gabalin in improving sleep quality and depression in hemo- dialysis patients with peripheral neuropathy: A randomized prospective crossover trial. Int Urol Nephrol. 2013. Jun, 45(3). 831–837. https://doi.10.1007/s11255-012-0193-1.
19. Xavier Basurto Ona, Dimelza Osorio, Xavier Bonfill Cosp. Drug therapy for treating post‐dural puncture heada- che. Cochrane Database Syst Rev. 2015. 7. 78–87. https:// doi.10.1002/14651858.cd007887.pub3.
20. Linde M., Mulleners W.M., Chronicle E.P., McCrory D.C. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013. 6: CD010609. https://doi.10.1002/14651858.cd010609.
21. Gabapentin for chronic neuropathic pain and fibro- myalgia in adults / Moore RA, Wiffen PJ, Derry S. [et al.] // Cochrane Database Syst Rev. 2014. Apr 27. CD007938. https:// doi.10.1002/14651858.CD007938.pub3.
22. Panebianco M, Al-Bachari S, Hutton JL, Marson AG Gabapentin add‐on treatment for drug‐resistant focal epilepsy. Cochrane Database Syst Rev. 2021. Jan 12. 1(1): CD001415. https://doi.10.1002/14651858.CD001415.pub4.
23. Sarah J Nevitt, Maria Sudell, Sofia Cividini, Anthony G Marson, Catrin Tudur Smith. Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database Syst Rev. 2022. Apr 1; 4(4): CD011412. https://doi.10.1002/14651858.cd011412.pub4.
 24. Moore J, Gaines C. Gabapentin for chronic neuropathic pain in adults. Br J Community Nurs. 2019. 24(12). 608–609. https://doi.10.12968/bjcn.2019.24.12.608.
25. Garcia D. Gabapentin for Chronic Neuropathic Pain. Am Fam Physician. 2015 Dec 1; 92(11): Online. PMID: 26760423.
26. Levine AR, Carrasquillo L, Mueller J, Nounou MI, Naut ER, Ibrahim D. Pharmacotherapy. High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retro- spective Cohort Analysis. Pharmacotherapy. 2019 Sep; 39(9). 881–888. https://doi.0.1002/phar.2309.
27. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Bego- vic A. Gabapentin treatment for alcohol dependence: a rando- mized clinical trial. JAMA Intern Med. 2014. 174(1). 70–7. https:// doi.0.1001/jamainternmed.2013.11950.
28. Raymond F. Anton, Patricia Latham, Konstantin Vo- ronin, et al. Efficacy of Gabapentin for the Treatment of Al- cohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020. May 1;180(5).728–736. https://doi.10.1001/jamain- ternmed.2020.0249.
29. Samuel M Tiglao, Erica S Meisenheimer, Robert C Oh. Alcohol Withdrawal Syndrome: Outpatient Management. Am Fam Physician. 2021.104(3). 253–262.
30. Alex Andaluz, Dustin DeMoss, Cynthia Claassen et al. Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study. Am J Drug Alcohol Abuse. 2020. 46(1). 49–57. https://doi.10.10 80/00952990.2019.1634085.
31. Saeed Ahmed, Ramya Bachu, Padma Kotapati et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Front Psychiatry. 2019. May 7. 10: 228. https://doi.10.3389/fpsyt.2019.00228.
32. John Marsden, Martin White, Fizz Annand et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry. 2019. Nov, 6(11), 935–950. https://doi.10.1016/ S2215-0366(19)30331-1.
33. Neuropathic pain in adults: pharmacological management in non-specialist settings: Clinical guideline [CG173]. Published: 20 November 2013. Last updated 22 September 2020. https:// www.nice.org.uk/guidance/cg173.
34. Clinical Guidelines: Consensus on the Best Practices in Pain Medicine. The American Academy of Pain. 2022. URI: https:// painmed.org/clinical-guidelines/.
35. Birse F., Derry S., Moore R. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 May 16; 2012(5): CD009485. doi: 10.1002/14651858. CD009485.pub2.
36. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. Nov-Dec 2003. 9(6). 559–568. https://doi.org/10.18553/jmcp.2003.9.6.559.